Refractive Surgery Devices Market to Reach USD 393.12 Million by 2030 - An Insightful Analysis of Industry Growth, Trends, and Forecasts
22 févr. 2024 04h09 HE
|
Research and Markets
Dublin, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The "Global Refractive Surgery Devices Market by Product Type (Aberrometers, Microkeratome, Ophthalmic Laser), Application (Astigmatism, Dry Eyes,...
Global Ophthalmic Drugs Market Size is Estimated to Reach USD 62.55 billion by 2030, Growing at a CAGR of 7.4%: Straits Research
21 févr. 2024 10h20 HE
|
Straits Research
New York, United States, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Anti-infectives in a product designed specifically to be injected into or applied to the eye or eyes are known as ophthalmic...
OTC Dry Eye Drops Market to Surge to USD 8.40 Billion by 2034, Thanks to Rising Prevalence of Dry Eye Syndrome and Technological Advancements
05 févr. 2024 04h36 HE
|
Research and Markets
Dublin, Feb. 05, 2024 (GLOBE NEWSWIRE) -- The "Global OTC Dry Eye Drops Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's offering. With dry eye...
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
31 janv. 2024 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Jan. 31, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
Global Artificial Tear Market Forecast to 2030 Featuring Analysis of J&J Vision Care, Allergan, Alcon, Bausch & Lomb, Santen, URSAPHARM Arzneimittel, and ROHTO Pharmaceutical
24 janv. 2024 05h07 HE
|
Research and Markets
Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "Artificial Tear Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. With...
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
08 janv. 2024 07h00 HE
|
OKYO Pharma LTD
Statistically significant drug effects were observed in FDA-recognized efficacy endpoints as early as the 15-day first visit after dosingStatistically significant improvement was observed in both a...
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
04 déc. 2023 07h00 HE
|
OKYO Pharma LTD
LONDON and NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of...
OTC Dry Eye Drops Market Size, Share & Trends Analysis Report 2023-2030: Rising Digital Screen Usage Fuels Global OTC Dry Eye Drops Market Growth
20 nov. 2023 08h18 HE
|
Research and Markets
Dublin, Nov. 20, 2023 (GLOBE NEWSWIRE) -- The "OTC Dry Eye Drops Market Size, Share & Trends Analysis Report By Type (Branded, Generics), By Product Type, By Viscosity, By Distribution Channel,...
Dry Eye Treatment Devices Market Trends Analysis Report 2023-2030 with Competitive Analysis of Sight Sciences, Lumenis, ESW Vision, Johnson & Johnson, Alcon, & MiBo Medical Group
24 oct. 2023 11h18 HE
|
Research and Markets
Dublin, Oct. 24, 2023 (GLOBE NEWSWIRE) -- The "Dry Eye Treatment Devices Market Size, Share & Trends Analysis Report By Technology (MGX, Combination (MGX+IPL)), By End-use (Hospitals, Ophthalmic...
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
05 oct. 2023 07h00 HE
|
OKYO Pharma LTD
Over 95% of randomized DED patients have completed 4 weeks of dosing in the planned 12-week Phase 2 trial, with 72% of randomized DED patients completing 8 weeks, and 7.1% of patients completing the...